160 related articles for article (PubMed ID: 18851703)
1. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases.
Jennings GT; Bachmann MF
Annu Rev Pharmacol Toxicol; 2009; 49():303-26. PubMed ID: 18851703
[TBL] [Abstract][Full Text] [Related]
2. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.
Ambühl PM; Tissot AC; Fulurija A; Maurer P; Nussberger J; Sabat R; Nief V; Schellekens C; Sladko K; Roubicek K; Pfister T; Rettenbacher M; Volk HD; Wagner F; Müller P; Jennings GT; Bachmann MF
J Hypertens; 2007 Jan; 25(1):63-72. PubMed ID: 17143175
[TBL] [Abstract][Full Text] [Related]
3. Design of novel vaccines based on virus-like particles or chimeric virions.
Bárcena J; Blanco E
Subcell Biochem; 2013; 68():631-65. PubMed ID: 23737067
[TBL] [Abstract][Full Text] [Related]
4. Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines.
Link A; Bachmann MF
Immunotherapy; 2010 Jul; 2(4):561-74. PubMed ID: 20636009
[TBL] [Abstract][Full Text] [Related]
5. Vaccines against non-communicable diseases.
Röhn TA; Bachmann MF
Curr Opin Immunol; 2010 Jun; 22(3):391-6. PubMed ID: 20338740
[TBL] [Abstract][Full Text] [Related]
6. A virus-like particle-based anti-nerve growth factor vaccine reduces inflammatory hyperalgesia: potential long-term therapy for chronic pain.
Röhn TA; Ralvenius WT; Paul J; Borter P; Hernandez M; Witschi R; Grest P; Zeilhofer HU; Bachmann MF; Jennings GT
J Immunol; 2011 Feb; 186(3):1769-80. PubMed ID: 21191068
[TBL] [Abstract][Full Text] [Related]
7. Virus-like particles: potential veterinary vaccine immunogens.
Liu F; Ge S; Li L; Wu X; Liu Z; Wang Z
Res Vet Sci; 2012 Oct; 93(2):553-9. PubMed ID: 22100244
[TBL] [Abstract][Full Text] [Related]
8. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
Arora U; Tyagi P; Swaminathan S; Khanna N
Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
[TBL] [Abstract][Full Text] [Related]
9. Study designs for the nonclinical safety testing of new vaccine products.
Forster R
J Pharmacol Toxicol Methods; 2012 Jul; 66(1):1-7. PubMed ID: 22561062
[TBL] [Abstract][Full Text] [Related]
10. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses.
Chackerian B; Rangel M; Hunter Z; Peabody DS
Vaccine; 2006 Sep; 24(37-39):6321-31. PubMed ID: 16806604
[TBL] [Abstract][Full Text] [Related]
11. Nonclinical safety assessment of vaccines and adjuvants.
Wolf JJ; Kaplanski CV; Lebron JA
Methods Mol Biol; 2010; 626():29-40. PubMed ID: 20099119
[TBL] [Abstract][Full Text] [Related]
12. Design of clinical trials for therapeutic cancer vaccines development.
Mackiewicz J; Mackiewicz A
Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
[TBL] [Abstract][Full Text] [Related]
13. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
14. Papillomavirus-like particles and HPV vaccine development.
Schiller JT; Lowy DR
Semin Cancer Biol; 1996 Dec; 7(6):373-82. PubMed ID: 9284529
[TBL] [Abstract][Full Text] [Related]
15. Use of animal models in the development of human vaccines.
Gerdts V; Littel-van den Hurk Sv; Griebel PJ; Babiuk LA
Future Microbiol; 2007 Dec; 2(6):667-75. PubMed ID: 18041907
[TBL] [Abstract][Full Text] [Related]
16. CEA-based vaccines.
Huang EH; Kaufman HL
Expert Rev Vaccines; 2002 Jun; 1(1):49-63. PubMed ID: 12908512
[TBL] [Abstract][Full Text] [Related]
17. Virus-like particles in vaccine development.
Roldão A; Mellado MC; Castilho LR; Carrondo MJ; Alves PM
Expert Rev Vaccines; 2010 Oct; 9(10):1149-76. PubMed ID: 20923267
[TBL] [Abstract][Full Text] [Related]
18. Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG.
Song S; Wang Y; Zhang Y; Wang F; He Y; Ren D; Guo Y; Sun S
Cancer Lett; 2007 Oct; 256(1):90-100. PubMed ID: 17656012
[TBL] [Abstract][Full Text] [Related]
19. Murine polyomavirus virus-like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer.
Tegerstedt K; Franzén AV; Andreasson K; Joneberg J; Heidari S; Ramqvist T; Dalianis T
Anticancer Res; 2005; 25(4):2601-8. PubMed ID: 16080500
[TBL] [Abstract][Full Text] [Related]
20. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
